Quốc gia: Canada
Ngôn ngữ: Tiếng Anh
Nguồn: Health Canada
DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE); TIMOLOL (TIMOLOL MALEATE)
GENERIC MEDICAL PARTNERS INC
S01ED51
TIMOLOL, COMBINATIONS
20MG; 5MG
SOLUTION
DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) 20MG; TIMOLOL (TIMOLOL MALEATE) 5MG
OPHTHALMIC
10ML
Prescription
BETA-ADRENERGIC AGENTS
Active ingredient group (AIG) number: 0237301001; AHFS:
APPROVED
2015-02-19
_MED-DORZOLAMIDE-TIMOLOL_ _ _ _(dorzolamide hydrochloride and timolol maleate) _ _Page 1 of 36 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR MED-DORZOLAMIDE-TIMOLOL Dorzolamide and Timolol Ophthalmic Solution Solution, 20 mg/mL dorzolamide hydrochloride and 5 mg/mL timolol maleate, Ophthalmic BP Elevated Intraocular Pressure Therapy Topical Carbonic Anhydrase Inhibitor and Topical Beta-Adrenergic Blocking Agent Generic Medical Partners Inc. 1500 Don Mills Road, Suite 711 Toronto, Ontario, M3B 3K4 Date of Initial Authorization: FEB 27, 2015 Date of Revision: Dec 30, 2022 Submission Control Number: 269684 _MED-DORZOLAMIDE-TIMOLOL_ _ _ _(dorzolamide hydrochloride and timolol maleate) _ _Page 2 of 36 _ RECENT MAJOR LABEL CHANGES Not applicable. TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ........................................................................................... 2 TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ...................................................................... 4 1 INDICATIONS .............................................................................................................. 4 1.1 Pediatrics .......................................................................................................... 4 1.2 Geriatrics........................................................................................................... 4 2 CONTRAINDICATIONS ................................................................................................. 4 4 DOSAGE AND ADMINISTRATION ................................................................................. 5 4.1 Dosing Considerations ....................................................................................... 5 4.2 Recommended Dose and Dosage Adjustment ..................................... Đọc toàn bộ tài liệu